SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 7, 2002
CRYOLIFE, INC.
(Exact name of registrant as specified in its charter)
Florida
(State or other jurisdiction of incorporation)
1-13165 59-2417093
(Commission File Number) (IRS Employer Identification No.)
1655 Roberts Boulevard N.W., Kennesaw, Georgia 30144
(Address of principal executive offices, including zip code)
(770) 419-3355
(Registrant's telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Item 4. Changes in Registrant's Certifying Accountant.
On May 7, 2002, CryoLife, Inc. ("CryoLife") engaged Deloitte & Touche, LLP
("Deloitte") as its independent auditors. The decision to engage Deloitte was
recommended by the Audit Committee and was approved by the Board of Directors of
CryoLife. The engagement will be effective immediately. Deloitte replaces the
firm of Arthur Andersen LLP as independent auditors of CryoLife. On April 9,
2002, CryoLife dismissed Arthur Andersen as its independent auditors.
Neither CryoLife nor anyone engaged on its behalf has consulted with Deloitte
during CryoLife's two most recently completed fiscal years or during its current
fiscal year with regard to either: (i) the application of accounting principles
to a specified transaction, either completed or proposed, or the type of audit
opinion that might be rendered on CryoLife's financial statements; or (ii) any
matter that was either the subject of a disagreement (as defined in Item
304(a)(1)(iv) of Regulation S-K and the related instructions) or a reportable
event (as described in Item 304(a)(1)(v) of Regulation S-K).
CryoLife hereby incorporates by reference herein the information set forth in
its press release dated May 7, 2002, a copy of which is attached hereto as
Exhibit 99.1
Item 7. Financial Statements and Exhibits.
(a) Financial Statements.
Not applicable.
(b) Pro Forma Financial Information.
Not applicable.
(c) Exhibits.
Exhibit Number Description
99.1 Press Release dated May 7, 2002
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, CryoLife
has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
CRYOLIFE, INC.
Date: May 10, 2002 By: /s/ D. Ashley Lee
--------------------------------
Name: D. Ashley Lee
Title: Vice President, Chief
Financial Officer
3
EXHIBIT INDEX
Exhibit Number Description Page
99.1 Press Release dated May 7, 2002
1461480
EXHIBIT 99.1
[GRAPHIC OMITTED]
NEWS RELEASE
FOR IMMEDIATE RELEASE
Contact: D. Ashley Lee
Vice President, Chief Financial Officer
(800) 438-8285
CRYOLIFE, INC. APPOINTS NEW ACCOUNTING FIRM
Atlanta, GA ...(May 7, 2002)...CryoLife, Inc. (NYSE: CRY), a life-science
company involved in the development and commercialization of cryopreserved and
tissue-engineered implantable heart valves, vascular and orthopaedic grafts, and
surgical adhesives, announced that its Board of Directors has appointed the
accounting firm of Deloitte & Touche, LLP as the Company's independent auditors.
Founded in 1984, CryoLife, Inc. is the leader in the development and
commercialization of implantable living human tissues for use in cardiovascular,
vascular and orthopaedic surgeries throughout the United States and Canada. The
Company's BioGlue(R) surgical adhesive is FDA approved as an adjunct to sutures
and staples for use in adult patients in open surgical repair of large vessels
and is CE marked in the European Community and approved in Canada and Australia
for use in vascular and pulmonary sealing and repair. The Company also
manufactures the SynerGraft(R) heart valve and the SynerGraft vascular graft,
the world's first tissue-engineered heart valve and vascular replacement,
respectively, and the CryoLife-O'Brien(R) and CryoLife-Ross(R) stentless porcine
heart valves, which are CE marked for distribution within the European
Community. The human heart valves and vascular grafts processed by CryoLife
using the SynerGraft technology are distributed in the U.S. under the trade
names of CryoValve(R)SG and CryoVein(R)SG, respectively.
For additional information about the company, visit CryoLife's web site:
http://www.cryolife.com -END-
1461480